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Noncolorectal gastrointestinal (GI) malignancies are among the most frequently diagnosed cancers. Despite the
undeniable progress in systemic treatments in recent decades, further improvements using cytotoxic chemo-
therapy seem unlikely. In this setting, recent discoveries regarding the mechanism underlying immune evasion
have prompted the study of molecules capable of inducing strong antitumor responses. Thus, according to early
data, immunotherapy is a very promising tool for the treatment of patients with GI malignancies. Noncolorectal
GI cancers are a major public health problem worldwide. Traditional treatment options, such as chemotherapy,
surgery, radiation therapy, monoclonal antibodies and antiangiogenic agents, have been the backbone of
treatment for various stages of GI cancers, but overall mortality remains a major problem. Thus, there is a sub-
stantial unmet need for new drugs and therapies to further improve the outcomes of treatment for
noncolorectal GI malignancies. ‘‘Next-generation’’ immunotherapy is emerging as an effective and promising
treatment option in several types of cancers. Therefore, encouraged by this recent success, many clinical trials
evaluating the efficacy of immune checkpoint inhibitors and other strategies in treating noncolorectal GI
malignancies are ongoing. This review will summarize the current clinical progress of modern immunotherapy
in the field of noncolorectal GI tumors.
KEYWORDS: Immunotherapy; Gastrointestinal; Neoplasms.
’ INTRODUCTION
Gastrointestinal (GI) cancers represent the most common
malignancy worldwide (1). Colorectal, gastric and liver cancers
rank second, third and fourth in cancer-related mortality,
respectively (2). Although early-stage GI cancers are amen-
able to surgical resection with curative intent, 25-50% of
patients develop metastatic disease during follow-up. More-
over, approximately 25% of GI cancers are diagnosed at an
advanced, incurable stage (3,4).
Despite the recent progress in diagnosis and treatment,
including the introduction of targeted therapies, patients
with advanced GI cancer still fare particularly poorly (5,6).
In the last years, advances in the understanding of the inter-
section between immune surveillance and tumor growth have
led to broad therapeutic advances in many cancer types. For
example, we observed significant improvements in the overall
survival and treatment response duration in some solid tumors,
such as melanoma, non-small cell lung cancer and geni-
tourinary cancers, as well as in hematologic malignancies (7).
Additionally, the recognition of some aspects of the patho-
genesis of GI malignancies has rendered immunotherapy a
promising tool in the management of GI cancer.
The idea that at least some GI cancers are ‘‘immunogenic
enough’’ to be treated in clinical trials of immune-directed
therapies initially arose from the observation that chronic
infections and the associated inflammation are well-known
risk factors for some GI cancers. For example, hepatitis B and
C (HCV) are related to liver cancer, and Helicobacter pylori is
a major risk factor for gastric adenocarcinoma. Irritants such
as tobacco or asbestos are not only carcinogenic but can also
trigger chronic inflammation. Finally, inflammatory bowel
disease significantly increases colorectal cancer risk. Inflam-
mation generally leads to genomic instability, accompanied
by the accumulation of mutations and neoantigens. Reinfor-
cing these findings, vast epidemiological data suggest that
aspirin, which is a well-known anti-inflammatory agent, has
protective antitumor effects against several cancer types,
including colorectal cancer (8).
Considering these aspects of GI cancer pathogenesis and
the impressive results observed in other solid tumors, several
studies have been conducted to assess the activity of next-
generation immunotherapy in patients with digestive tract
tumors. Despite the relatively slow pace of immunotherapy
development in GI cancers, initial results suggest that thisDOI: 10.6061/clinics/2018/e510s
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approach may be effective (9). Preliminary results from
phase 1 and 2 trials in esophageal, gastric and hepatobiliary
cancer report response rates ranging from 15% to 25%, similar
to the response rates described for other malignancies (10).
Given the recent abundance of information on immuno-
therapy in GI tumors, we conducted a comprehensive review
of the clinical trials evaluating immune-directed therapies in
noncolorectal GI cancers, with a focus on immune check-
point (ICP) inhibitors.
’ CLINICAL EVIDENCE OF IMMUNOTHERAPY
IN NONCOLORECTAL GASTROINTESTINAL
MALIGNANCIES
Esophageal Squamous Cell Carcinoma
In patients with advanced esophageal squamous cell carci-
noma (SCC), immunotherapy has shown promising results.
Table 1 summarizes the data from prospective trials of ICP
inhibitors conducted in esophageal cancer. KEYNOTE-028 is
a phase 1b study that tested the anti-programmed cell death
protein 1 (PD-1) monoclonal antibody pembrolizumab (10 mg/kg
every two weeks) in 83 patients with advanced esophageal
squamous carcinoma and adenocarcinoma that presented
positive immunohistochemical expression of programmed
cell-death receptor ligand 1 (PD-L1). In a heavily pretreated
population (87% of whom had undergone X2 prior thera-
pies for metastatic disease), the overall response rate was
30.4% (29.4% in SCC). Some tumor shrinkage was observed in
52.2% of the patients, and the side effects were manageable.
Only four patients experienced grade 3 treatment-related
adverse events; these events included lymphopenia, anorexia,
liver disorder and generalized rash (11).
An early uncontrolled trial (ONO-4538-07) of nivolumab
(3 mg/kg every two weeks), which is another anti-PD-1 agent,
in refractory metastatic esophageal SCC (irrespective of posi-
tive immunochemical PD-L1 expression) showed objective
responses in 11 of 64 assessable patients (17%). The median
time to progression was 2.8 months, and the median overall
survival time was 10.8 months. Again, the safety profile was
expected and manageable (12).
Esophagogastric Adenocarcinoma
Early attempts to employ immunotherapy in gastric cancer
were disappointing. Interferon (IFN) activity could not be
demonstrated in either the adjuvant or metastatic settings
(13,14). Similarly, early trials using vaccines in the setting of
advanced disease failed to demonstrate any benefit. Never-
theless, later vaccine trials indicated that patients who could
mount a tumor-specific immune response had better survival
than those who could not (15,16). Thus, there is a subgroup of
patients who might benefit from immunotherapy, and this
characteristic is being explored in recent trials of ICP inhibitors.
Checkpoint Inhibitors. Table 2 summarizes the current
data on ICP inhibitors in gastric cancer. The activity of pembro-
lizumab in advanced gastric cancer was first tested in the phase
1b trial KEYNOTE-012. In this study, among 39 patients treated
with pembrolizumab (10 mg/kg every two weeks), the objec-
tive response rate was 22%, the median progression-free
survival time was 1.9 months and the median overall survival
time was 11.4 months (17).
KEYNOTE-059 is a multicohort trial testing pembrolizumab
in patients with advanced gastroesophageal adenocarcinoma (18). Ta
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Cohort 1 consisted of 259 patients who had undergone at
least two prior lines of therapy. All patients received 200 mg
intravenous (IV) pembrolizumab every three weeks. In cohort
1, 57% of the patients were PD-L1 positive. The response rate
was 12% in the overall population (16% in PD-L1-positive
patients and 6% in PD-L1-negative patients); complete
responses were observed in 3% of the patients, regardless of
tumor PD-L1 status. The median overall survival time was
5.5 months. Grade 3-5 adverse events occurred in 18% of the
patients and included two deaths. Five patients experienced
grade 3 immune-mediated adverse events. Microsatellite
instability (MSI) was investigated in 174 patients, of whom
4% presented high-frequency MSI (MSI-High); the objective
response rate was 57.1% in the MSI-High patients but only
9.0% in the non-MSI-High group (19). Based on these data,
the Food and Drug Administration (FDA) approved pem-
brolizumab for use in patients with PD-L1 positive meta-
static esophagogastric adenocarcinomas after two other
lines of treatment had been attempted.
KEYNOTE-059 cohort 2 consisted of 25 untreated PD-L1-
unselected patients treated with chemotherapy (cisplatin and
fluoropyrimidine) plus pembrolizumab. Of the tumors, 64%
were PD-L1-positive. The response rate was 60% in the entire
cohort (69% in PD-L1-positive patients and 38% in PD-L1-
negative patients), and complete responses were observed in
4% of the patients (all with PD-L1-negative tumors). The
median overall survival time was 13.8 months. Cytopenias
attributed to chemotherapy were the main toxicities reported.
Grade 3 immune-mediated adverse events were observed in
16% of patients (mainly skin toxicity) (18). Cohort 3 recruited
31 newly diagnosed PD-L1-positive, HER-2-negative patients.
All received pembrolizumab monotherapy as a first-line
regimen, with promising results: an overall response rate
of 26% and a median overall survival time of 20.7 months.
Adverse events occurred in 77% of the patients (a 23%
incidence of grade 3-5 adverse events) (18).
CheckMate 032 (20) is a phase 1/2 trial that enrolled
160 Western patients pretreated (4 1 line) for advanced
gastroesophageal cancer. The patients were distributed
into three different groups. The primary endpoint was the
overall response rate, and no statistical comparisons were
made across the groups. In cohort 1, 59 patients received
3 mg/kg nivolumab every two weeks, and 38% of the
tumors were PD-L1-positive. The overall response rate and
complete response rate were 12% and 2%, respectively, and
the median overall survival time was 6.2 months. Grade 3-4
serious adverse events occurred in 5% of the patients. In cohort
2, 49 patients received 1 mg/kg nivolumab plus ipilimumab,
which is an anti-cytotoxic T lymphocyte-associated protein 4
(CTLA4) monoclonal antibody, at a dosage of 3 mg/kg every
three weeks; 24% of the tumor samples were PD-L1 positive.
The overall response rate was 24%, and the median overall
survival time was 6.9 months; 35% of the patients experienced
grade 3-4 serious adverse events. Finally, in cohort 3, in which
30% of the tumor samples were PD-L1-positive, 52 patients
received 3 mg/kg nivolumab plus 1 mg/kg ipilimumab every
three weeks. The response rate was 8%, and the median overall
survival time was 4.8 months. Grade 3-4 serious adverse events
occurred in 17% of the patients.
The recently published phase 3 trial ATTRACTION-2
included 493 Asian patients with advanced gastric and eso-
phagogastric junction adenocarcinoma who had been treated
with at least two prior lines of treatment; these patients were
randomized for treatment with 3 mg/kg nivolumab every
two weeks or with placebo (21). No patient selection based
on PD-L1 expression or mismatch repair proficiency status was
conducted. The median overall survival time was 5.26 months
in the nivolumab arm and 4.14 months in the placebo arm
(HR = 0.63, p o 0.0001). The twelve-month overall survival
rates in the nivolumab and placebo arms were 26.2% and
10.9%, respectively. In this study, PD-L1 expression did not
predict survival benefit. Toxicity of any grade occurred in
43% of the patients in the nivolumab arm (grade 3-4 toxicity
occurred in 10%). This trial is the first phase 3 trial showing
the survival benefit of immunotherapy in esophagogastric
cancer, and based on these results, nivolumab was approved
in Japan in September 2017 for use in patients with esophago-
gastric adenocarcinoma who have undergone two or more
prior lines of treatment.
In 2017, the Food and Drug Administration (FDA) approved
pembrolizumab for patients with mismatch repair-deficient
(dMMR) tumors based on the impressive results achieved in a
prospective phase 2 study; this approval is the FDA’s first
tissue/site-agnostic approval (22). In this trial, 86 previously
treated patients with Lynch syndrome-related dMMR tumors
(mostly colorectal, but the trial included five patients with
esophagogastric cancer) received pembrolizumab monother-
apy. The objective response rate was 40% in the colorectal
cohort and 57% (4 of 7 patients) in the noncolorectal cohort.
The average time to response was 21 weeks, and the median
overall survival time had not yet been reached. Toxicity was
considered mild, but endocrine disorders were observed in
21% of patients.
The phase 1b study JAVELIN assessed the activity of the
anti-PD-L1 monoclonal antibody avelumab (10 mg/kg every
two weeks) in 151 patients with advanced esophagogastric
cancer (as either second-line therapy or maintenance therapy
after first-line therapy) (23). The unconfirmed response rate
was 9.7% and 9.0% in the second-line and maintenance groups,
respectively. Among PD-L1-positive patients in the second-line
setting, the response rate was 18.2%. Grade 3 adverse events
occurred in 9.9% of the patients. Despite exciting early phase
data, two recently published phase 3 trials did not show a clear
survival gain with immunotherapy. In JAVELIN GASTRIC 300,
(24) 371 patients were randomized to avelumab (10 mg/kg
every two weeks) or the physician’s choice of chemotherapy
(paclitaxel or irinotecan) or best supportive care after having
undergone prior treatment with 2 or more lines of therapy; the
patients achieved a median overall survival of 4.6 m versus 5.0
months (HR:1.1, CI 0.9 -1.4, p=0.81). The KEYNOTE-061 trial
(25) randomized 592 patients who experienced progression
with first-line platinum/fluoropyrimidine treatment to either
pembrolizumab or standard-dose paclitaxel. Overall survival
results were disappointing, with median overall survival times
of 9.1 months for pembrolizumab and 8.3 months for paclitaxel
(HR: 0.82, CI: 0.66 - 1.03, one-sided p=0.04). Post hoc analysis
showed that patients whose tumors had CPS >10% or MSI-H
experienced improved survival with pembrolizumab.
Importantly, recent data show that the activity of different
classes of ICP inhibitors in esophagogastric cancer may vary.
For example, anti-CTLA4 antibodies seem to have little, if any,
activity in these tumors. An initial trial with the anti-CTLA4
monoclonal antibody tremelimumab showed disappointing
results (26). Similarly, no survival benefit from maintenance
ipilimumab therapy was seen in a recently published phase 2
trial (27) in which 114 patients with advanced gastroesophageal
cancer who had achieved an outcome of at least stable disease
after first-line treatment were randomized to ipilimumab
4
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treatment (10 mg/kg every three weeks for four doses,
followed by 10 mg/kg every 12 weeks for up to three years)
or best supportive care. The primary endpoint of immune-
related progression-free survival (irPFS) in the ipilimumab arm
was 2.92 months, versus 4.90 months in the comparator arm.
These results led to study cessation.
’ HEPATOPANCREATOBILIARY CANCER
Pancreatic Cancer
Vaccines. Vaccines are the most frequently investigated
form of immunotherapy in pancreatic cancer. Unfortunately, the
results so far have been rather disappointing. The activity
of the cell-based vaccine algenpantucel-L, which is derived
from two irradiated pancreatic cancer cell lines (HAPa-1 and
HAPa-2) transmuted to express the murine alpha-1,3-galactosyl-
transferase enzyme, has recently been evaluated in a phase 3
trial (IMPRESS). In this trial, 722 patients were randomized to
receive either algenpantucel-L in combination with standard
of care or standard of care alone after pancreatic cancer
resection. The median overall survival was 27.3 months in
the algenpantucel-L arm and 30.4 months in the control arm
(not significantly different) (28). In addition, two protein-
based vaccines have been evaluated in the advanced disease
setting. In the TeloVac trial, 1062 patients with locally
advanced or metastatic pancreatic cancer were randomized
to receive chemotherapy (capecitabine and gemcitabine),
sequential chemoimmunotherapy or concurrent chemoim-
munotherapy (29). A human telomerase reverse transcriptase
catalytic subunit peptide vaccine was used as immunother-
apy. No differences in overall survival time were observed
(chemotherapy alone: 7.9 months; sequential chemoimmuno-
therapy: 6.9 months; concurrent chemoimmunotherapy:
8.4 months). Another large randomized trial evaluated the
activity of the gastrin immunogen peptide-based vaccine
G17DT in patients with pancreatic cancer unsuited for or
unwilling to receive chemotherapy (30). In this trial, seventy-
nine patients received treatment with G17DT, and 75 patients
received placebo. Overall, no differences in survival were
observed. In a post hoc analysis, patients who developed
an anti-G17DT response experienced longer overall survival
times than those who did not develop this response.
Recent trials have tried to boost vaccine effectiveness by
using attenuated or killed bacteria as immune modulators.
In an initial trial, 90 patients with metastatic pancreatic cancer
were randomized (2:1) to immunotherapy using GVAX/
cyclophosphamide in combination with CRS-207 (a live-
attenuated formulation of mesothelin-expressing Listeria
monocytogenes) or GVAX/cyclophosphamide alone (31).
Patients treated with the immunomodulator had longer sur-
vival times than those who were not (6.1 vs. 3.9 months,
respectively). Moreover, patients with enhanced mesothelin-
specific CD8 T-cell responses experienced improved out-
comes. Nevertheless, the ECLIPSE trial showed that this
boosted immunotherapy regimen was no more effective than
standard chemotherapy (32). In this study, 303 patients were
randomized (1:1:1) to receive GVAX/cyclophosphamide +
CRS-207, CRS-207 alone or chemotherapy (physician’s choice).
No differences in median overall survival times were observed
(GVAX/cyclophosphamide+ CRS-207: 3.8 months; CRS-207:
5.4 months; chemotherapy: 4.6 months). In another trial
(IMAGE-1), 110 patients with locally advanced or metastatic
pancreatic cancer were randomized (2:1) to receive gemcitabine+
IMM-101 or gemcitabine alone (33). IMM-101 is an immuno-
modulator derived from heat-killed Mycobacterium obuense.
Despite an improvement in the progression-free survival time
in patients receiving the immunomodulator (HR = 0.58, 95%
CI 0.37 0,91; p = 0.16), no differences were observed in the
overall survival time (gemcitabine + IMM-101: 6.7 months;
gemcitabine: 5.6 months). Thus, previous vaccine studies in
pancreatic cancer did not achieve clinically meaningful results.
However, the role of vaccine-mediated immunotherapy in
pancreatic cancer cannot be ruled out, as some studies have
shown that patients mounting an adequate response to
immunotherapy survived longer than those who did not.
As a result, a new generation of cancer-directed vaccine trials
using recent immunological knowledge is underway.
Checkpoint Inhibitors. To date, ICP inhibitors have
shown disappointing activity in pancreatic cancer. The efficacy
of ipilimumab has been assessed in three prospective studies.
In the first study, 27 patients with locally advanced or meta-
static pancreatic cancer were treated with 3 mg/kg ipilimumab
every three weeks for four cycles (34). One patient experi-
enced a delayed partial response after initial disease pro-
gression. Additionally, minor responses were seen in two
patients. The median overall survival time was approxi-
mately 20 weeks. A phase 1b trial evaluated the activity and
safety of 10 mg/kg ipilimumab every three weeks for four
cycles either alone or in combination with the cell-based
vaccine GVAX (35). The median overall survival time was
3.6 months for ipilimumab monotherapy and 5.7 months for
combination treatment (p = 0.072). No response according to
RECIST was observed. Recently, ipilimumab was combined
with gemcitabine in a small phase 1b trial (36). Among
16 patients, two experienced a partial tumor response and
five experienced stable disease as best response. The median
progression-free survival time was 2.5 months, and the median
overall survival time was 8.5 months.
In addition, trials were performed to evaluate the role of
anti-PD-1 or anti-PD-L1 antibodies in patients with pancreatic
cancer. In a phase 1 study, 14 patients with pancreatic cancer
were treated with the anti-PD-L1 antibody BMS-936559, but no
responses were observed (37). An additional trial evaluated the
activity of the anti-PD-L1 antibody durvalumab (MEDI-4736)
in 25 patients with pancreatic cancer (38). Partial responses
were observed in 3 patients, and the disease control rate (DCR)
at 12 weeks was 21%. Finally, in a recent phase 1 study,
17 patients with pancreatic cancer were treated with nivolumab
and nab-paclitaxel (arm A; n = 11) or with nivolumab, gemci-
tabine and nab-paclitaxel (arm B; n = 6). Responses according
to RECISTwere seen in both arms (arm A: two responses, arm
B: three responses) (39).
The particularly disappointing results of the ICP inhibitor
studies conducted so far in pancreatic cancer are the con-
sequence of a complex interplay among the tumor cells, tumor
microenvironment, microbiome and immune system (40).
Pancreatic cancer cells can induce the expression of proteins
(e.g., CTLA4, or PD-L1) and the secretion of cytokines (e.g.,
GM-CSF) that prevent effector T cells from infiltrating and
destroying the tumor (40,41). Additionally, the tumor stroma
acts like a barrier, creating a hypovascular and hypoxic environ-
ment that blocks the penetration of small molecules (42).
Finally, the presence of certain bacteria has been shown to
facilitate the development of pancreatic cancer, possibly by
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inducing an inflammatory state (43). The next generation of
trials in pancreatic cancer will certainly address this complexity
by targeting multiple tumor- and microenvironment-related
pathways and exploring newer immunological strategies.
Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC), the most common pri-
mary hepatic tumor, develops from chronic inflammation
induced by carcinogens, such as alcohol, or by infections, such
as viral hepatitis B and HCV. Thus, immunotherapy might be
effective in treating HCC. However, the results of the initial
immunotherapy studies in HCC have not been very promis-
ing. Randomized trials evaluating the role of IFN in patients
with advanced HCC (44,45) and in the adjuvant setting (46,47)
had disappointing results. Another approach to immunother-
apy in HCC is adoptive cell therapy. In randomized trials in an
adjuvant setting, treatment with autologous cytokine-induced
killer (CIK) lymphocytes led to improvements in recurrence-
free survival and/or overall survival times (48-51). Despite
some methodological issues in these studies, this approach
has been proved feasible, and new trials evaluating these
approaches to immunotherapy in HCC are underway.
Checkpoint Inhibitors. In a small phase 1/2 trial,
17 patients with advanced HCC secondary to HCV infection
were treated with the anti-CTLA4 antibody tremelimumab
at a dosage of 15 mg/kg every 90 days (52). The objective
response rate was 17.6%, and 45% of the patients experi-
enced disease control for at least 6 months. The activity and
safety of the anti-PD-L1 antibody durvalumab was assessed
in a phase 1 trial that enrolled 40 patients (93% of whom
had been previously treated with sorafenib) (53). The objec-
tive response rate was 10.3%, and 33.3% of the patients
experienced disease control for at least 6 months. Patients
with cirrhosis secondary to HCV seemed to derive the
greatest benefit from durvalumab. The largest study to date
to investigate the efficacy of ICP inhibitors in HCC was the
expanded cohort of the phase 1/2 CheckMate 040 trial (54),
in which 262 patients with HCC (most of whom had been
previously treated with sorafenib) were treated with nivolu-
mab at a dosage of 3 mg/kg every two weeks. The overall
objective response rate was 19%, with a median response
duration of 9.9 months. Three patients (1%) experienced
radiological complete response. The DCR was 64%, and 37%
of the patients experienced disease control for at least 6
months. The median progression-free survival time was 4.0
months, and the median overall survival time had not been
reached at the end of the trial. The efficacy outcomes were
similar between subgroups of patients with viral hepatitis
and alcohol-induced liver disease. These results led to the
accelerated FDA approval of nivolumab in September 2017
as a second-line treatment of HCC. Similar results were shown
with pembrolizumab in the KEYNOTE-224 (55). In this phase II
study, 104 patients with advanced HCC were treated with
pembrolizumab 200 mg every 3 weeks. The overall response
and disease control rates were 17 and 61%, respectively. The
median progression-free and overall survival times were 4.9
and 12.9 months, respectively. In an attempt to improve the
effectiveness of immunotherapy for HCC, 40 patients were
enrolled in a phase 1 trial evaluating the activity of the combi-
nation of durvalumab and tremelimumab. The overall response
rate was 20%, and the DCR at 16 weeks was 57.5% (56).
Given the promising results of ICP inhibitors in HCC, further
data are expected regarding combination immunotherapy for
HCC treatment.
Biliary Tract Cancer
Only one study has evaluated the role of ICP inhibitors
in advanced biliary tract cancer. In KEYNOTE-028, 24
patients with PD-L1-positive tumors (X 1%) were treated
with pembrolizumab at a dosage of 10 mg/kg every two weeks
until confirmed progression or unacceptable toxicity occur-
red or until two years of treatment were completed. Partial
response and stable disease were each seen in four patients.
Among the responders, the treatment duration was longer
than 40 weeks (57). Additionally, patients with biliary cancers
were enrolled in the noncolorectal cohort in the phase 2 trial of
pembrolizumab for the treatment of dMMR tumors, and the
overall response rate of the cohort was 71% (58).
Neuroendocrine Tumors
Neuroendocrine tumors (NETs) are a heterogeneous group
of tumors that range from well-differentiated tumors, i.e.,
G1 and G2 NETs, to high-grade aggressive cancers (poorly
differentiated G3 carcinomas). Immunotherapy has been
restricted to well-differentiated tumors; IFN has the longest
history of use. Studies of IFN-alpha monotherapy have
generally shown tumor stabilization, measured by various
methods, in 50 to 70% of patients with previously progres-
sive GI NETs and have shown improvement in 30 to 70% of
patients with carcinoid symptoms (59).
A recent phase 1b trial, KEYNOTE 028, tested pembro-
lizumab monotherapy in pretreated patients with well-
differentiated carcinoid tumors (mostly midgut NETs) and
pancreatic NETs (60). Approximately 20% of the 35 carcinoid
tumors and 24.5% of the pancreatic NETs were PD-L1-
positive. The overall response was 12% among the carcinoid
tumors and 6% in the pancreatic NET cohort, but no com-
plete responses were observed. The median progression-free
survival time was less than 6 months in both groups, but
durable responses were observed. The median response
duration was 9.2 months for patients with carcinoid tumors
and 20.3 months for patients with pancreatic NETs, and the
median overall survival time was 20.1 months for both cohorts.
However, no study has evaluated immunotherapy for the
treatment of high-grade NETs. This subgroup is hetero-
geneous and comprises NETs with a high ki67 index and
poorly differentiated neuroendocrine carcinomas (NECs).
Both subgroups are molecularly distinct; studies have shown
that poorly differentiated NECs display molecular alterations
that resemble their carcinoma/adenocarcinoma counterparts,
such as mismatch repair deficiency, which has been observed
in approximately 10% of gastric and colorectal NECs (61).
Therefore, although the further exploration of immuno-
therapy for the treatment of well-differentiated NET can be
rationalized, the proper identification of immunogenic sub-
groups is crucial to prove the benefit of checkpoint inhibi-
tors in NET treatment. For patients with NECs, a MSI-H or
dMMR status should be determined; pembrolizumab is
an effective treatment option for MSI-H- or dMMR-positive
patients.
Predictive Biomarkers
As previously shown, despite the relatively short progres-
sion-free survival time observed in most clinical trials, a sub-
group of patients has experienced a durable tumor response
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in almost every study. However, few studies have evaluated
predictive biomarkers for immunotherapy response in GI
cancers. As a marker of PD-1/PD-L1 inhibitory pathway acti-
vation, PD-L1 has been analyzed by immunohistochemistry
in many types of tumor specimens to try to predict the
benefit of immunotherapy. Different antibodies have been
used in studies evaluating anti-PD-1 or anti-PD-L1 anti-
bodies, so the generalization of the resulting data may be
flawed. Similarly, heterogeneity in tumor PD-L1 expression
may hamper the correlation of PD-L1 expression with clinical
benefit from immunotherapy. Moreover, PD-L1 expression
may change during tumor progression; thus, the results may
differ depending on the time of biopsy. Additionally, PD-L1
expression may be different in tissues from primary and
metastatic tumors. Finally, no standardized cutoff value
for PD-L1 expression has been validated, and some studies
with anti-PD-1 agents have shown responses (even complete
responses) in tumors not expressing PD-L1 (62).
In gastric cancer, limited data relate tumor PD-L1 expres-
sion and the objective response rate to immunotherapy.
In the phase 1b JAVELIN study, patients with tumors with
higher expression levels of PD-L1 were more likely to exhibit
tumor response during treatment with avelumab (23) in both
the second-line and maintenance settings than those with
lower tumor PD-L1 expression. Additionally, in the KEYNOTE-
059 trial (cohorts 1 and 2) (19,63), patients with a PD-L1
expression of X 1% had higher response rates to pembro-
lizumab (or pembrolizumab plus chemotherapy, for cohort 2).
However, complete responses have been reported in patients
with PD-L1-negative gastric cancers treated with pembroli-
zumab (cohort 1 of KEYNOTE-059). Interestingly, in the
KEYNOTE-012 trial, among patients with PD-L1-positive
tumors (PD-L1 expression ofX 1%), those with tumors with
higher mononuclear inflammatory density scores were more
likely to exhibit tumor response (17). However, despite this
evidence, in the only randomized phase III clinical trial of
anti-PD-1 immunotherapy in gastric cancer published so far
(ATTRACTION-2), no differences in survival benefit were
seen between patients with PD-L1-positive tumors and those
with PD-L1-negative tumors (21). Additionally, in HCC, no
association has been shown between tumor PD-L1 expres-
sion and the response rate to nivolumab (54). Therefore, PD-
L1 expression does not currently seem accurate enough to
guide treatment decisions regarding the use of ICP inhibitors
in GI malignancies. Future studies should examine the molec-
ular subtypes of gastric cancers that are more ‘‘immunogenic’’
and are thus more likely to respond to ICP inhibitors, such as
the Epstein-Barr-virus associated type (64).
MSI-H has emerged as a potential predictor of immuno-
therapy response, regardless of the primary tumor site.
Tumors with this molecular abnormality present a high
mutational load and neoantigen formation, the latter of
which may facilitate immune recognition and the activation
of an antitumor response (58). Neoantigen formation has
been found in many tumor types (Table 3), including several
GI malignancies (65). Studies have shown that patients with
MSI are more likely to respond to immunotherapy than those
without MSI. Higher response rates to pembrolizumab
have been found in patients with MSI-H gastric cancer in
the KEYNOTE-012 (2 of 4) and KEYNOTE-059 (4 of 7)
trials (17,19). Additionally, in a study assessing the activity
of pembrolizumab in many MSI-H tumor types (including
ampullary carcinoma, cholangiocarcinoma, pancreatic cancer,
small bowel cancer and gastric cancer), 8 of 17 patients showed
a tumor response to treatment, with durable responses seen in
most of these patients (66). An additional study showed a clear
correlation between MSI-H and a benefit from ICP inhibitors
(22). Thus, in May 2017, the FDA approved pembrolizumab
for the treatment of patients with MSI-H tumors that have
been previously treated. Nevertheless, patients with non-
MSI-H tumors have also responded to immunotherapy (19).
In KEYNOTE-059 (cohort 2), 9% of patients with non-MSI-H
tumors showed a tumor response to pembrolizumab. However,
although the MSI-H status selects for patients likely to bene-
fit from ICP inhibitors, prospective studies have shown that
patients with non-MSI-H tumors may also respond to this
treatment strategy.
Another predictive biomarker of the checkpoint inhibitor
response, which is associated with but independent of MSI-H
status, is a high tumor mutational burden. The rationale
behind this biomarker is that the higher the tumor mutation
burden is, the higher the probability of neoantigen forma-
tion. Therefore, other genetic conditions associated with high
mutational tumor burdens, such as POLE mutations (germline
and somatic), which are found in rare cases of endometrial (67)
or GI malignancies (68), will likely predict a great benefit from
ICP inhibitors.
Despite the clear ability of MSI-H to predict ICP inhibitor
response, no perfect biomarker for selecting patients for
immunotherapy has been found. Further development in
this field is necessary for the accurate selection of patients
for treatment with checkpoint inhibitors (69). Additionally,
combined biomarker strategies are promising; such strategies
are superior to single biomarkers for predicting the response
to immunotherapy (70).
’ PERSPECTIVES AND CONCLUSIONS
Advances in basic immunology have led to the discovery
of PD-1, PD-L1 and CTLA4 as targets to promote the immune
response against cancer cells. However, this new era in onco-
logy is just beginning. New T cell inhibitory proteins (e.g.,
LAG-3, TIM-3 and VISTA) and T cell stimulatory molecules
(e.g., ICOS/ICOSL and CD27/CD70) that are important
Table 3 - Frequency of microsatellite instability (MSI) in noncolorectal gastrointestinal malignancies.
Tumor MSI-H$ Retrospective Series (%) MSI-H$ TCGA (%) (62)
Esophageal adenocarcinoma 6.5 (77) 1.6
Gastric carcinoma 8.2-37.0 (78) 19.0
Cholangiocarcinoma 0.0-42.0 (79) 1.3
Pancreatic adenocarcinoma 0.3-22.0 (80-84) 0.0
Small bowel adenocarcinoma 7.6-28.0 (85-87) -
Ampullary carcinoma 6.0-10.0 (88-90) -
Hepatocellular carcinoma 11.0-16.0% (91,92) 0.8
$MSI-H: high-frequency microsatellite instability.
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regulators of immune surveillance have been discovered,
and directed therapies are being developed (71). Addition-
ally, some elements of the innate immune response, such as
pathways inhibiting macrophages and natural killer cells, as
well as the immunosuppressive enzyme IDO (indoleamine-
2,3-dioxygenase), have been shown to be upregulated in
cancer; thus, additional studies are warranted to assess the
feasibility and activity of agents inhibiting such elements of
the immune response (71). Moreover, trials evaluating the
role of monoclonal antibody combinations targeting different
inhibitory pathways are underway. Additionally, as immu-
notherapy resistance mechanisms are increasingly recog-
nized, more effective drugs can be developed (69). Finally,
progress in molecular engineering has led to the develop-
ment of chimeric antigen receptor T cells (CAR-T cells) (72),
which have demonstrated impressive results in acute lympho-
blastic leukemia (73) and promising activity in early studies in
GI tumors (74-76).
Of equal importance, as the number of targetable molec-
ules increases, we should be able to improve our capability to
properly select patients for specific immune-based therapies.
Clearly, the current methodology of assessing PD-L1 expres-
sion is not accurate enough to predict who will benefit from
ICP inhibitors. Similarly, if we use MSI status, which is a rare
biological phenomenon, as the sole criterion to select patients
for treatment with anti-PD-1/PD-L1 inhibitors, most of the
patients who would potentially respond to this treatment
would not have access to these drugs. Thus, further develop-
ments in this field are necessary in order to maximize treat-
ment efficacy.
In conclusion, the emerging landscape of anticancer immuno-
therapy is encouraging, and novel strategies are expected to
dramatically change the standard of care for noncolorectal GI
malignancies. Not only are new drugs awaited, but further
developments in patient selection also appear very important
in the pursuit of better outcomes for patients with GI cancers.
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